Cargando…
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175266/ https://www.ncbi.nlm.nih.gov/pubmed/34123730 http://dx.doi.org/10.1016/j.eucr.2021.101712 |
_version_ | 1783703018005331968 |
---|---|
author | Koguchi, Dai Tabata, Ken-ichi Tsumura, Hideyasu Mori, Kohei Koh, Hideshige Iwamura, Masatsugu |
author_facet | Koguchi, Dai Tabata, Ken-ichi Tsumura, Hideyasu Mori, Kohei Koh, Hideshige Iwamura, Masatsugu |
author_sort | Koguchi, Dai |
collection | PubMed |
description | Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of cisplatin for treating PCa patients with the breast cancer gene (BRCA)2 mutation. We administered 80 mg/m(2) cisplatin triweekly to a patient with metastatic castration-resistant PCa (mCRPC) with the BRCA2 mutation, and after ten cycles, the prostate-specific antigen was dramatically decreased. We suggest that BRCA2 mutations may indicate the use of cisplatin for treating patients with mCRPC. |
format | Online Article Text |
id | pubmed-8175266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81752662021-06-11 Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report Koguchi, Dai Tabata, Ken-ichi Tsumura, Hideyasu Mori, Kohei Koh, Hideshige Iwamura, Masatsugu Urol Case Rep Oncology Poly (ADP-ribose) polymerase inhibitors exhibit strong activity for treating the DNA damage repair defect in patients with prostate carcinoma (PCa). Although conventional DNA-damaging agents can theoretically lead to synthetic antitumoral effects, no report has clearly mentioned the clinical use of cisplatin for treating PCa patients with the breast cancer gene (BRCA)2 mutation. We administered 80 mg/m(2) cisplatin triweekly to a patient with metastatic castration-resistant PCa (mCRPC) with the BRCA2 mutation, and after ten cycles, the prostate-specific antigen was dramatically decreased. We suggest that BRCA2 mutations may indicate the use of cisplatin for treating patients with mCRPC. Elsevier 2021-05-17 /pmc/articles/PMC8175266/ /pubmed/34123730 http://dx.doi.org/10.1016/j.eucr.2021.101712 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Oncology Koguchi, Dai Tabata, Ken-ichi Tsumura, Hideyasu Mori, Kohei Koh, Hideshige Iwamura, Masatsugu Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title_full | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title_fullStr | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title_full_unstemmed | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title_short | Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report |
title_sort | effect of cisplatin on metastatic castration-resistant prostate cancer with brca2 mutation: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175266/ https://www.ncbi.nlm.nih.gov/pubmed/34123730 http://dx.doi.org/10.1016/j.eucr.2021.101712 |
work_keys_str_mv | AT koguchidai effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport AT tabatakenichi effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport AT tsumurahideyasu effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport AT morikohei effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport AT kohhideshige effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport AT iwamuramasatsugu effectofcisplatinonmetastaticcastrationresistantprostatecancerwithbrca2mutationacasereport |